Association of the British Pharmaceutical Industry (1999) Data Sheet Compendium 1999–2000.
London: Datapharm Publications Ltd.
Bazire, S. (1999) Psychotropic Drug Directory.
Wiltshire: Quay Books Division.
British Medical Association and Royal Pharmaceutical Society for Great Britain (2000) British National Formulary.
London & Wallingford: BMJ Books & Pharmaceutical Press.
Calabrese, J. R., Bowden, C. L., Sachs, G. S., et al (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 study group. Journal of Clinical Psychiatry, 60, 79–88.
Chadwick, D. (1987) Overuse of monitoring of blood concentrations of antiepileptic drugs (Letter). BMJ, 294, 723–724.
Choonara, L. A. & Rane, A. (1990) Therapeutic monitoring of anticonvulsants. State of the art. Clinical Pharmacokinetics, 18, 318–328.
Commission on Antiepileptic Drugs & International League Against Epilepsy (1993) Guidelines for therapeutic monitoring of antiepileptic drugs. Epilepsia, 34, 585–587.
Eadie, M. J. (1995) The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant treatment. Clinical Pharmacokinetics, 29, 29–35.
Eadie, M. J. (1998) Therapeutic drug monitoring – antiepileptic drugs. British Journal of Clinical Pharmacology, 46, 185–193.
Johannessen, S. I. (1997) Plasma drug concentration monitoring of anticonvulsants: practical guidelines. CMS Drugs, 7, 349–365.
Maidment, I. (1999) Update on the use of new anticonvulsants as mood stabilisers. Psychiatric Bulletin, 23, 554–558.
Pisani, F., Eazio, A., Artesic, C., et al (1987) An epidemiological study of the clinical impact of pharmacokinetic anticonvulsant drug interactions based on serum drug level analysis. Italian Journal of Neurological Science, 8, 135–141.
Schmidt, D. & Siemes, H. (1998) The role of liver function tests in monitoring anticonvulsant use. CNS Drugs, 10, 321–328.
Schoenberger, R. A.
Tanasijevic, M. J., Jha, A., et al (1995) Appropriateness of antiepileptic drug level monitoring. Journal of the American Medical Association, 27, 1622–1626.
Sharpe, P. C., Morrow, J. & Trimble, E. R. (1995) An audit of therapeutic drug monitoring of anticonvulsants. Ulster Medical Journal, 64, 151–156.
Sobotka, J. L., Alexander, B. & Cook, B. L. (1990) A review of carbamazepine's hematologic reactions and monitoring recommendations. The Annals of Pharmacotherapy, 24, 1214–1219.
Taylor, D., McConnell, D., McConnell, H., et al (1999) The Bethlem and Maudsley NHS Trust Prescribing Guidelines (5th edn). London: Martin Dunitz.
Taylor, D., Starkey, K. & Ginary, S. (2000) Prescribing and monitoring of carbamazepine and valproate – a case note review. Psychiatric Bulletin, 24, 174–177.
Woo, E., Chan, Y. M., Yu, Y. L., et al (1988) If a well-established epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomised prospective study. Epilepsia, 29, 129–139.
Wyllie, E. & Wyllie, R. (1991) Routine laboratory monitoring for serious effects of antiepileptic medications: the controversy. Epilepsia, 32 (Suppl. 5), 574–579.